STOCK TITAN
  1. Home
  2. News
  3. ARCT

Arcturus Therapeutics Holdings Inc. - ARCT STOCK NEWS

Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.

Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.

Key projects in Arcturus' pipeline include:

  • LUNAR-OTC for treating ornithine transcarbamylase deficiency
  • LUNAR-CF aimed at cystic fibrosis
  • LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively

Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.

Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.

Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.

News

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®. ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg). The study included healthy adults initially immunized with two doses of an mRNA vaccine (Comirnaty® or Spikevax™) and then a third dose of Comirnaty® at least three months prior to the booster dose of either ARCT-154 or Comirnaty® in the study. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
-
News

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Rhea-AI Summary
CSL and Arcturus Therapeutics Announce Positive Phase 3 Results for ARCT-154 Sa-mRNA COVID-19 Vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
-
News

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. (ARCT) to present at the 42nd Annual J.P. Morgan Healthcare Conference. The President & CEO will discuss the company's focus on mRNA medicines for infectious diseases and rare liver and respiratory conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences
News

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics receive historic approval for ARCT-154, the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine in Japan. This marks a significant milestone in CSL's promise to develop and deliver innovative vaccines to combat respiratory viral diseases, expanding their comprehensive portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
-
News

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

Rhea-AI Summary
CSL (CSL; CSLLY) and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA COVID-19 vaccine. This marks the first sa-mRNA vaccine in the world to be registered, highlighting CSL's commitment to global public health. The vaccine is approved for initial vaccination and booster for adults 18 years and older, based on positive clinical data from several studies. CSL Seqirus, in partnership with Meiji Seika Pharma, will distribute the vaccine in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
-
News

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. (Arcturus, Nasdaq: ARCT) has received Orphan Drug Designation from the FDA for ARCT-032 to treat cystic fibrosis. The company remains on track to share interim Phase 1b data in H1 2024, with the first patient in the study successfully completing two administrations of the product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.9%
Tags
clinical trial
News

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. (ARCT) extends expected cash runway to 2026, achieves $35 million milestone under CSL collaboration, and provides corporate updates. The company reports financial results for Q3 2023 and highlights progress in expanding its next-generation STARR vaccine platform, COVID vaccine development, and mRNA therapeutic pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.08%
Tags
earnings
-
News

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023

Rhea-AI Summary
Arcturus Therapeutics will release its financial results for the quarter ended September 30, 2023 on November 14. They will also host a conference call and webcast on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences earnings
-
News

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Rhea-AI Summary
Arcturus Therapeutics to participate in investor and scientific conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences
News

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government

Rhea-AI Summary
Arcalis, a manufacturing joint venture of Arcturus Therapeutics in Japan, has been awarded $165 million by the Japanese government to construct a DNA template manufacturing facility and develop mRNA-based vaccines. This funding will support the rapid manufacture of various vaccines and therapeutics, investigational drugs, and mRNA-based medicines. The new facility aims to accelerate vaccine production and deliver vaccines within 100 days of the declaration of a target viral strain. This development positions Arcalis as a leader in the production of effective novel vaccines and mRNA-based medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none

FAQ

What is the current stock price of Arcturus Therapeutics Holdings (ARCT)?

The current stock price of Arcturus Therapeutics Holdings (ARCT) is $16.91 as of November 22, 2024.

What is the market cap of Arcturus Therapeutics Holdings (ARCT)?

The market cap of Arcturus Therapeutics Holdings (ARCT) is approximately 462.7M.

What does Arcturus Therapeutics specialize in?

Arcturus Therapeutics specializes in developing RNA-based medicines for rare diseases, particularly focusing on liver and respiratory conditions.

What are the core technologies of Arcturus Therapeutics?

Arcturus' core technologies include the LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA).

What kind of diseases is Arcturus targeting with its therapies?

Arcturus targets rare diseases such as ornithine transcarbamylase deficiency, cystic fibrosis, and viral infections like influenza and COVID-19.

What recent collaborations has Arcturus entered into?

Arcturus has recently partnered with PassPort Technologies Inc. to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics.

What is Kostaive®?

Kostaive® is the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine developed by Arcturus.

Who are Arcturus' major partners?

Arcturus collaborates globally with CSL Seqirus for mRNA vaccines and has a joint venture in Japan, ARCALIS, focusing on mRNA vaccine and therapeutic manufacturing.

What is LUNAR-OTC?

LUNAR-OTC is a therapeutic candidate in Arcturus' pipeline aimed at treating ornithine transcarbamylase deficiency.

How extensive is Arcturus' patent portfolio?

Arcturus holds over 400 patents and patent applications issued across the U.S., Europe, Japan, China, and other countries.

Where is Arcturus Therapeutics headquartered?

Arcturus is headquartered in San Diego, California.

How can I get more information about Arcturus Therapeutics?

For more detailed information, visit their official website at www.ArcturusRx.com, and connect with them on Twitter and LinkedIn.

Stock ARCT logo
Arcturus Therapeutics Holdings Inc.

Nasdaq:ARCT

ARCT Rankings

#3185 Ranked by Market Cap
N/A Ranked by Dividends

ARCT Stock Data

462.65M
24.80M
8.46%
90.21%
16.91%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO